Gilead Sciences, Inc.

Nathan E Wright

James G Taylor

Jeromy J Cottell

Sheila M Zipfel

Chienhung Chou

Zheng-Yu Yang

Gediminas J Brizgys

Elizabeth M Bacon

Elbert Chin

Stephen E Ammann

Scott D Schroeder

John O Link

Chao-I Hung

Marilyn Ndukwe

William John Watkins

Gary Bruce Phillips

Thorsten A Kirschberg

Musong Kim

Neil H Squires

Gayatri Balan

Roland D Saito

Chien-Hung Chou

James S Cassidy

Kavoos Kolahdouzan

Christopher T Clark

Kirk L Stevens

Rhiannon Thomas-Tran

Manoj C Desai

Eda Y Canales

Jiayao Li

Nathan D Shapiro

Eric Gorman

Suzanne M Szewczyk

Stephen Ammann

Michael L Mitchell

Marina Shatskikh

Daniel G Shore

Michael Graupe

Jennifer R Zhang

Winston C Tse

David W Lin

Ezra Roberts

Megan K Armstrong

Gary Phillips

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.

Pyrrolo[1,2-b]pyridazine derivatives

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Cot modulators and methods of use thereof

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.

A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.

Thiadiazole IRAK4 inhibitors

Growing community of inventors

Foster City, CA, United States of America

Nathan E Wright